Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB020 in Healthy Subjects

Next Previous
Trial Profile

A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB020 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etokimab (Primary) ; Etokimab (Primary)
  • Indications Asthma; Atopic dermatitis; Peanut hypersensitivity
  • Focus Adverse reactions; First in man
  • Sponsors AnaptysBio

Most Recent Events

  • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 24 Feb 2017 Status changed from active, no longer recruiting to completed.
  • 13 Feb 2017 According to an AnaptysBio media release, data from this trial will be presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting and the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top